Platinum-resistant in 244 epithelial ovarian carcinomas and the effect of chemosensitivity on prognosis

Zeng Haoxia,Liang Xudong,Cui Heng

2010-01-01

Abstract:Objective:To investigate clinical features of epithelial ovarian carcinoma,response rate to platinum-based combination chemotherapy and the effects of chemosensitivity on prognosis.Method:According to the length of disease free interval(DFI),244 patients were divided into 3 groups:platinum-resistant,partially sensitive,platinum-sensitive groups.The differences of clinical features,relapse treatment and prognosis were compared among the 3 groups.Results:In 244 patients with epithelial ovarian carcinoma,the median age was 52 years,72.1% was advanced stage,61.1% was serous cancer,67.2% was poorly differentiated,rate of lymph node metastasis was 31.2%.The primary resistant rate to platinum-based chemotherapy was 23.36%.The five-year survival rate was 54.7%,median OS was 70 months,and the median PFS was 29 months.The platinum resistant percentage of patients with advanced stage and patients without optimal cytoreductive surgery was higher(P<0.001,P<0.001).Platinum-resistant patients' CA125 and lymph node metastasis rate were higher than those of platinum-sensitive patients(P=0.03,P=0.003).There were significant differences among the 3 groups in overall survival(OS) and progression-free survival(P<0.001).Partially sensitive patients who were treated with other chemotherapy regimen after disease relapse had a little longer OS than patients with platinum-based combination chemotherapy(P=0.196).Conclusion:Advanced ovarian cancers with poor differentiation,lymph node metastasis,high CA125 level,and failed to achieve optimal cytoreductive surgery are much more likely to resistant or partially sensitive to platinum.Patients with different response to platinum-based combination chemotherapy have different prognosis.Different treatment should be chosen for relapse.